Study: CBD Improves Frequency and Severity of Seizures and Reduces Adverse Events

The use of cannabidiol (CBD) “improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study” published by the journal Epilepsy and Behavior.

The objective of this study “was to characterize the changes in adverse events, seizure severity, and frequency in response to a pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex®) in a large, prospective, single-center, open-label study.”

Researchers initiated CBD in 72 children and 60 adults with treatment-resistant epilepsy (TRE) at 5 mg/kg/day and titrated it up to a maximum dosage of 50 mg/kg/day. At each visit, researchers “monitored treatment adverse events with the adverse events profile (AEP), seizure severity using the Chalfont Seizure Severity Scale (CSSS), and seizure frequency (SF) using seizure calendars.” They “analyzed data for the enrollment and visits at 12, 24, and 48 weeks”, and “recorded AEP, CSSS, and SF at each follow-up visit for the weeks preceding the visit (seizures were averaged over 2-week periods).”

Continue reading

Study: Cannabis May Help Reduce Aggressive Behavior in Autism Patients

Cannabis may help reduce the aggressive behavior experienced by some autism patients, according to a study published by the journal Frontiers in Cellular Neuroscience.

“Understanding neuronal mechanisms underlying aggression in patients with autism spectrum disorder (ASD) could lead to better treatments and prognosis”, begins the study’s abstract. “The Neuroligin-3 (NL3)R451C mouse model of ASD has a heightened aggressive phenotype, however the biological mechanisms underlying this behavior are unknown.”

Given that “[e]ndocannabinoids influence social interaction and aggressive behavior”, researchers “studied the effects of cannabinoid receptor 1 (CB1) agonist on NL3R451C mice.”

Continue reading

Marijuana Use Doesn’t Lead to Deficits Associated With Schizophrenia, Finds Study

Contrary to arguments oft-used by opponents of marijuana and marijuana law reform, “cannabis use does not significantly compound the gray matter deficits associated with schizophrenia”.

This is according to a study published by the journal Psychiatry Research: Neuroimaging, and conducted by researchers at Vanderbilt University Medical Center in Tennessee.

The study’s abstract starts by stating that; “Substance use may confound the study of brain structure in schizophrenia. We used voxel-based morphometry (VBM) to examine whether differences in regional gray matter volumes exist between schizophrenia patients with and without clinically significant cannabis and/or alcohol use histories compared to 88 healthy control subjects.”

Continue reading

Study: Cannabis May Help Control Hospital and Community-Acquired MRSA

The “leaf extracts of cannabis sativa” has “potential for the control of both hospital- and community-acquired MRSA”, according  to a new study being published by the Journal of Integrative Medicine, and epublished ahead of print by the U.S. National Institute of Health.

“This study examined the antimicrobial activity of Cannabis sativa, Thuja orientalis and Psidium guajava against methicillin-resistant Staphylococcus aureus (MRSA)”, states the study’s abstract.

For the study, “In vitro antimicrobial activities of the ethanolic extracts of C. sativa, T. orientalis and P. guajava were tested against MRSA”, and the “presence of bioactive molecules in these three leaves was evaluated using biochemical assays and high-performance thin-layer chromatography (HPTLC).”

Continue reading

10 Most Important Cannabis Studies Release in 2018 So Far

Even though it’s far from over, 2018 has been a stellar year for cannabis research. Here’s a look at the most important studies released so far.

Hundreds of cannabis-related studies have been released this year. A huge amount of these studies came to the conclusion that cannabis is beneficial in a wide-range of medical ailments, with others showing that its prohibition is detrimental to individuals and society as a whole. As difficult as it was to do so, we’ve narrowed these studies down to the 10 most important, with a few honorable mentions.

Continue reading

In June, Oregon Garnered $8.5 Million in Taxes from Legal Marijuana Sales

According to the Oregon Department of Revenue, the state made over $8.5 million in taxes from legal marijuana sales in June.

The $8,560,616 million in taxes came from the sale of roughly $45 million worth of marijuana and marijuana products (such as edibles and oils). The taxes garnered is slightly less than the $9 million made last month, but isn’t far off from the single-month record of $9.3 million made in January.

Of the $8.5 million in marijuana taxes Oregon made in June, $7.41 million came from the state’s 17% tax on marijuana sales. The remaining $1.49 million came from local taxes (which vary, but legally can’t be above 3%).

Continue reading

Study: CBD Increases Comfort in Dogs with Osteoarthritis

The most recent issue of the journal Frontiers presents findings of the first pharmacokinetic study and clinical trial on the use of cannabinoids to treat dogs with osteoarthritis and multi-joint pain.

The objective of this double-blind, placebo-controlled study was to “determine basic oral pharmacokinetics, and assess safety and analgesic efficacy of a cannabidiol (CBD) based oil in dogs with osteoarthritis (OA).”

In conducting their study, researchers found that “canine brief pain inventory and Hudson activity scores showed a significant decrease in pain and increase in activity with CBD oil.” Veterinary assessment “showed decreased pain during CBD treatment”, while “No side effects were reported by owners”.

Continue reading

Study: Marijuana Use Not Associated With Increased Risk of Dating Abuse

Same day marijuana use isn’t associated with an elevated risk of dating abuse, according to a new study published in the journal Violence Against Women, and published online by the National Institute of Health.

“The purpose of this study was to investigate same-day alcohol or marijuana use and dating abuse (DA) perpetration in a sample of 60 noncollege-attending young adults”, states the study’s abstract.

Participants reported daily data over a three month period. It was found that “DA perpetration was more likely on days when participants also reported alcohol use, but analyses of the temporal order indicated that alcohol use was not a proximal predictor of DA.” Same day marijuana use “was not associated with elevated risk of DA perpetration.”

Continue reading

There Was $129 Million in Marijuana and Marijuana Products Sold in Colorado in June

Those in Colorado purchased over $129 million worth of marijuana and marijuana products in June, a roughly 5% increase from the month prior.

In total there was $129,523,030 in marijuana and marijuana products purchased legally in Colorado in June, according to new data released by the state’s Department of Revenue. This is a slight increase from the amount sold in May ($122 million) and April ($124), but falls short of the record-setting $135 million sold in March.

Of the $129 million in marijuana sold in June, around $27 million came from the sale of medical marijuana, with the remainder from the sale of recreational marijuana. These sales helped Colorado garner around $20 million in tax revenue for the month of June.

Continue reading

Study: Cannabis Terpenes have “Anti-Inflammatory, Antioxidant, Analgesic, Anticonvulsive, Antidepressant, Anxiolytic, Anticancer, Antitumor, Neuroprotective, Anti-Mutagenic, Anti-Allergic, Antibiotic and Anti-Diabetic Attributes”

A new study has found that cannabis terpenes have attributes that are “anti-inflammatory, antioxidant, analgesic, anticonvulsive, antidepressant, anxiolytic, anticancer, antitumor, neuroprotective, anti-mutagenic, anti-allergic, antibiotic and anti-diabetic”.

The study was published by the European Journal of Medicinal Chemistry. It’s abstract starts by stating that “Cannabaceae plants Cannabis sativa L. and Humulus lupulus L. are rich in terpenes – both are typically comprised of terpenes as up to 3-5% of the dry-mass of the female inflorescence.” Some terpenes “are relatively well known for their potential in biomedicine and have been used in traditional medicine for centuries, while others are yet to be studied in detail.”

With that in mind, “The current, comprehensive review presents terpenes found in cannabis and hops.” They found that “Terpenes’ medicinal properties are supported by numerous in vitro, animal and clinical trials and show anti-inflammatory, antioxidant, analgesic, anticonvulsive, antidepressant, anxiolytic, anticancer, antitumor, neuroprotective, anti-mutagenic, anti-allergic, antibiotic and anti-diabetic attributes, among others.”

Continue reading